Drug Profile
Research programme: retroviral non-replicating vector based cancer immunotherapy - Forte Biosciences
Alternative Names: TOCA 621; Toca GammaLatest Information Update: 28 Mar 2022
Price :
$50
*
At a glance
- Originator Viagene Biotech
- Developer Forte Biosciences
- Class Gene therapies; Immunotherapies
- Mechanism of Action Gene transference; Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cancer; Malignant melanoma
Most Recent Events
- 28 Mar 2022 No recent reports of development identified for clinical-Phase-Unknown development in Malignant-melanoma in USA (Parenteral)
- 28 Mar 2022 No recent reports of development identified for preclinical development in Cancer in USA (Parenteral)
- 12 Mar 2020 Preclinical and clinical development is ongoing in USA (Parenteral)